ClinicalTrials.gg
Status unknownNCT03152708Updated Sep 21, 2017

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

An observational study in Glioblastoma, sponsored by CANbridge Life Sciences Ltd.. Status unknown. Per ClinicalTrials.gov, last updated 2017-09-21.

Sponsored by CANbridge Life Sciences Ltd. · Observational

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
62
Sex
All
01

Study summary

This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.

02

Conditions studied

  • Glioblastoma

Browse trials for

03

In context

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 62 is close to the median of 60 across 208 observational studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

CANbridge Life Sciences Ltd. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chinese GBM patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese nationality
  • No limits on Gender and age
  • First diagnosed GBM
  • Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV)

Exclusion criteria

Exclusion Criteria:

  • Other types of glioma by histological diagnosis
  • Tumor tissue not eligible for the central laboratory testing standard
  • No enough tumor tissue for the central laboratory test
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
62 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. CD95 Ligand Positive Rate

    Time frame: 0 day

Secondary outcomes

  1. CpG2 Positive Rate

    Time frame: 0 day

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2017; primary completion for Dec 2017, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2017
First posted
May 15, 2017
StartEst.
Nov 1, 2017
Primary completionEst.
Dec 1, 2017
CompletionEst.
Dec 31, 2017
Last update
Sep 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03152708
Lead sponsor
CANbridge Life Sciences Ltd.
Responsible party
Sponsor
First posted
May 15, 2017
Start date
Nov 1, 2017 (estimated)
Primary completion
Dec 1, 2017 (estimated)
Completion
Dec 31, 2017 (estimated)
Last update
Sep 21, 2017

Study contacts

Jack Hou
Contact
jhou@canbridgepharma.com
00862152996609
Jinsong Wu, MD
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion